Cargando…
eIF2β, a subunit of translation‐initiation factor EIF2, is a potential therapeutic target for non‐small cell lung cancer
To identify novel therapeutic targets for non‐small cell lung cancer (NSCLC), we conducted an integrative study in the following 3 stages: (i) identification of potential target gene(s) through shRNA functional screens in 2 independent NSCLC cell lines; (ii) validation of the clinical relevance of i...
Autores principales: | Tanaka, Ichidai, Sato, Mitsuo, Kato, Toshio, Goto, Daiki, Kakumu, Tomohiko, Miyazawa, Ayako, Yogo, Naoyuki, Hase, Tetsunari, Morise, Masahiro, Sekido, Yoshitaka, Girard, Luc, Minna, John D., Byers, Lauren A., Heymach, John V., Coombes, Kevin R., Kondo, Masashi, Hasegawa, Yoshinori |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5989750/ https://www.ncbi.nlm.nih.gov/pubmed/29624814 http://dx.doi.org/10.1111/cas.13602 |
Ejemplares similares
-
Identification of proteasomal catalytic subunit PSMA6 as a therapeutic target for lung cancer
por: Kakumu, Tomohiko, et al.
Publicado: (2017) -
Growth inhibitory effects of miR-221 and miR-222 in non-small cell lung cancer cells
por: Yamashita, Ryo, et al.
Publicado: (2015) -
Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis
por: Gen, Soei, et al.
Publicado: (2022) -
An EGFR-mutated Lung Adenocarcinoma Undergoing Squamous Cell Carcinoma Transformation Exhibited a Durable Response to Afatinib
por: Sato, Mitsuo, et al.
Publicado: (2018) -
Risk factors for pulmonary infection after diagnostic bronchoscopy in patients with lung cancer
por: Shimizu, Takahiro, et al.
Publicado: (2020)